Retrospective validation of clinical decision support tools for predicting outcomes in patients with IBD treated with vedolizumab

Description

In the last decade, more and more treatment options have become available for achieving and maintaining remission of inflammatory bowel disease (IBD), including monoclonal antibodies (mAb’s). It is of great value to be able to predict the treatment response before initiating therapy, both for the patient to get effective treatment as quickly as possible and for society considering that mAb’s often are very expensive. 
Recently, two clinical decision support tools (CDSTs) were developed to determine response probability of vedolizumab in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Because the CDSTs were developed with data from registration trials of vedolizumab, it is important to further validate these models with real world data (RWD) as conditions may differ. Several foreign RWD studies were already conducted but demonstrated conflicting results.
It is therefore important to further assess the applicability of the CDSTs for vedolizumab in both patients with CD and UC in the Netherlands. Additionally, the specificity of both CDSTs for vedolizumab is investigated by also including IBD patients treated with ustekinumab.         
After a pilot study in a medium-sized teaching hospital, a large study with a national IBD patient registry (ICC) is currently underway.

Who is the principal investigator? 

Dr. Luc Derijks

Team

Loriane Verleye (PhD-student)
Dr. Zlatan Mujagic (Maastricht UMC+)
Dr. Marjolijn Duijvestein (Radboud UMC)

Who is collaborating?

Initiative on Crohn and Colitis (ICC)

Contact for internship or collaboration and general questions

Dr. Luc Derijks (luc.derijks@mumc.nl)
Also, visit our Vacancies page.